Product Images Alfuzosin Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Alfuzosin Hydrochloride NDC 63629-2353 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
chemical-structure - chemical structure
figure-1 - figure 1
figure-2 - figure 2
The text contains a graph showing the Mean Change from Baseline in IPSS Total Symptom Score for two different treatments over a period of 84 days. The treatments are a placebo and Alfuzosin hydrochloride extended-release tablets. The graph shows that there was a statistically significant difference between the two treatments, with the Alfuzosin hydrochloride tablets showing better results at reducing symptoms. No further information is available from the given text.*
figure-3 - figure 3
The text describes a figure showing the mean change from baseline in the International Prostate Symptom Score (IPSS) Total Symptom Score over 28 to 56 days of treatment in two groups: one treated with a placebo (N=152) and the other treated with Alfuzosin hydrochloride extended-release tablets (N=137). The figure shows a statistically significant difference (p < 0.01) between the two groups.*
figure-4 - figure 4
The text describes the results of Trial 3 for the mean change from baseline in IPSS total symptom score over a period of 28-56 days of treatment with Aituzosin hydrochloride extended-release tablets compared to a Placebo. The sample size for Aituzosin hydrochloride extended-release tablets was 151 and for Placebo was 150. The results show a statistically significant improvement in symptoms (with **p <0.01) for the group treated with Aituzosin hydrochloride extended-release tablets compared to the placebo group.*
figure-5 - figure 5
The text is a statistical chart showing the mean change from baseline in peak urine flow rate in a medical trial involving a placebo group (N=167) and a group that took Alfuzosin hydrochloride extended-release tablets (N=170). The X-axis represents the days of treatment and the Y-axis represents the mean change in mL/s. The chart shows a statistically significant improvement in urine flow rate after treatment with Alfuzosin hydrochloride extended-release tablets.*
figure-6 - figure 6
figure-7 - figure 7
The figure shows the mean change from baseline in peak urine flow rate over a span of 84 days for two groups. One group consisted of 150 individuals who received a placebo, while the other group consisted of 151 individuals who received Alfuzosin hydrochloride extended-release tablets. The data suggest that there was no significant difference between the two groups in terms of peak urine flow rate (NS p > 0.05).*
Label - lbl636292353
This is a description of a medication called NILD, with a VSN #0516 YO. It contains Alfuzosin Hydrochloride, USP 10 mg, and is an extended-release tablet. The medication should be kept out of reach of children, stored between 20° and 25°C, and in a tight, light-resistant container with a child-resistant closure. It should also be protected from light and moisture. The NDC code is 63629-2353-1, and it comes in 1000 tablets.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.